Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Priority for Pediatric Cures Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · third_quarter · Q3
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · second_quarter · Q2
Source: Senate LDA
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Mikaela Naylon Give Kids a Chance Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Forest Service Accountability Act
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Consolidated Appropriations Act, 2026
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Mikaela Naylon Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Scientific EXPERT Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit
Give Kids a Chance Act of 2025
Client: RARE DISEASE COMPANY COALITION · Firm: RARE DISEASE COMPANY COALITION
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RARE DISEASE COMPANY COALITION via RARE DISEASE COMPANY COALITION
2026 · first_quarter · Q1
HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals
Proclamation 11020 - Section 232 Pharmaceutical Tariffs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE